Get the Stockscreener App
8.18
1.45%
-0.12
After Hours:
8.18
Amicus Therapeutics Inc stock is traded at $8.18, with a volume of 3.28M.
It is down -1.45% in the last 24 hours and up +2.38% over the past month.
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.
See More
Previous Close:
$8.30
Open:
$8.29
24h Volume:
3.28M
Relative Volume:
0.71
Market Cap:
$2.52B
Revenue:
$493.67M
Net Income/Loss:
$-104.69M
P/E Ratio:
-24.06
EPS:
-0.34
Net Cash Flow:
$-31.51M
1W Performance:
+0.25%
1M Performance:
+2.38%
6M Performance:
+26.23%
1Y Performance:
-22.10%
1-Day Range:
$8.00
$8.37
1-Week Range:
$8.00
$8.505
52-Week Range:
$5.51
$12.65
Amicus Therapeutics Inc Stock (FOLD) Company Profile
Name
Amicus Therapeutics Inc
Sector
Industry
Phone
(609) 662-2000
Address
47 HULFISH STREET, PRINCETON, NJ
Compare FOLD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FOLD
Amicus Therapeutics Inc
|
8.18 | 2.56B | 493.67M | -104.69M | -31.51M | -0.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-18-25 | Upgrade | Needham | Hold → Buy |
| Jul-17-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-13-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-06-24 | Initiated | Jefferies | Buy |
| May-30-24 | Initiated | Wells Fargo | Overweight |
| May-14-24 | Upgrade | Guggenheim | Neutral → Buy |
| Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-09-22 | Initiated | Morgan Stanley | Equal-Weight |
| Apr-13-22 | Resumed | Goldman | Neutral |
| Jan-14-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Nov-15-21 | Upgrade | Stifel | Hold → Buy |
| Sep-30-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-19-21 | Resumed | BTIG Research | Buy |
| May-27-21 | Initiated | Needham | Hold |
| May-21-21 | Initiated | UBS | Buy |
| Apr-14-21 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-02-21 | Initiated | Stifel | Hold |
| Feb-12-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-28-20 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-10-20 | Downgrade | Citigroup | Buy → Neutral |
| Nov-11-20 | Initiated | Berenberg | Hold |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Feb-04-20 | Resumed | Cantor Fitzgerald | Overweight |
| Nov-12-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-17-19 | Initiated | H.C. Wainwright | Buy |
| Jun-05-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Apr-05-19 | Initiated | Janney | Buy |
| Jan-30-19 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-29-18 | Initiated | Citigroup | Neutral |
| Aug-17-18 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-06-17 | Resumed | Goldman | Neutral |
| Sep-13-17 | Reiterated | Chardan Capital Markets | Buy |
| Aug-10-17 | Reiterated | Chardan Capital Markets | Buy |
| Jan-24-17 | Upgrade | Robert W. Baird | Neutral → Outperform |
| May-18-16 | Initiated | BofA/Merrill | Buy |
| Apr-14-16 | Initiated | Robert W. Baird | Neutral |
| Apr-12-16 | Reiterated | Chardan Capital Markets | Buy |
| Sep-16-15 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jun-16-15 | Reiterated | Chardan Capital Markets | Buy |
View All
Amicus Therapeutics Inc Stock (FOLD) Latest News
Why Amicus Therapeutics Inc. stock is a must watch in 2025Trade Volume Report & Consistent Profit Focused Trading Strategies - newser.com
How to escape a deep drawdown in Amicus Therapeutics Inc.Market Risk Summary & Reliable Intraday Trade Alerts - newser.com
Can Amicus Therapeutics Inc. stock maintain growth trajectoryWeekly Stock Report & Community Consensus Stock Picks - newser.com
Can volume confirm reversal in Amicus Therapeutics Inc.Fed Meeting & Fast Gain Stock Trading Tips - newser.com
What earnings revisions data tells us about Amicus Therapeutics Inc.Buy Signal & Technical Pattern Based Signals - newser.com
What Fibonacci levels say about Amicus Therapeutics Inc. reboundPortfolio Return Report & Consistent Profit Trade Alerts - newser.com
Will a bounce in Amicus Therapeutics Inc. offer an exitMarket Movers & Risk Controlled Stock Alerts - newser.com
Heatmap analysis for Amicus Therapeutics Inc. and competitorsEarnings Recap Summary & Entry Point Confirmation Signals - newser.com
What macro factors could drive Amicus Therapeutics Inc. (AM6) stock higherJuly 2025 Summary & Accurate Technical Buy Alerts - newser.com
Developing predictive dashboards with Amicus Therapeutics Inc. dataJuly 2025 Rallies & Fast Exit and Entry Strategy Plans - newser.com
Amicus Therapeutics Inc. stock prediction for this weekMarket Sentiment Report & High Accuracy Swing Trade Signals - newser.com
Is Amicus Therapeutics Inc. (AM6) stock trading at attractive multiplesPortfolio Gains Report & Risk Controlled Stock Pick Alerts - newser.com
Real time scanner hits for Amicus Therapeutics Inc. explainedJuly 2025 Selloffs & Verified Entry Point Detection - newser.com
Amicus Therapeutics (NASDAQ:FOLD) Given "Sell (E+)" Rating at Weiss Ratings - MarketBeat
Bayer Reports Positive Data on Cell Therapy for Parkinson's Disease - Nasdaq
Amicus Therapeutics (NASDAQ:FOLD) Upgraded to "Strong-Buy" at Zacks Research - MarketBeat
Q3 EPS Forecast for Amicus Therapeutics Lifted by Analyst - MarketBeat
What Does Wall Street Think About Amicus Therapeutics (FOLD)? - MSN
All You Need to Know About Amicus Therapeutics (FOLD) Rating Upgrade to Strong Buy - sharewise.com
Is Amicus Therapeutics Inc AM6 a good long term investmentVWAP Trading Strategies & Consistent Triple Returns - earlytimes.in
How the Narrative Around Amicus Therapeutics Is Shifting Amid Legal and Pipeline Developments - Yahoo Finance
Zacks.com featured highlights include Amicus Therapeutics, Micron Technology and General Dynamics - Yahoo Finance
Amicus Therapeutics (NASDAQ:FOLD) Shares Pass Above Two Hundred Day Moving AverageWhat's Next? - MarketBeat
Pompe Disease Market Research 2025: Treatment, Route of Administration, and Region Analysis and Fore - PharmiWeb.com
Pompe Disease Market Research 2025: Treatment, Route of Administration, and Region Analysis and Forecast to 2035 Featuring Amicus Therapeutics, Astellas, BioMarin, Maze Therapeutics, Oxyrane ParasailResearchAndMarkets.com - The AI Journal
Bet on These 3 Stocks With Upgraded Broker Ratings for Solid Returns - TradingView
What RSI levels show for Amicus Therapeutics Inc. (AM6) stockStop Loss & Weekly High Potential Stock Alerts - newser.com
A Look at Amicus Therapeutics’s Valuation After Analyst Upgrade and Improved Outlook (FOLD) - Yahoo Finance
Is Amicus Therapeutics Inc. (AM6) stock a top pick for value investorsWeekly Volume Report & Fast Gain Swing Alerts - newser.com
Market reaction to Amicus Therapeutics Inc.’s recent newsEarnings Overview Summary & Real-Time Chart Pattern Alerts - newser.com
How to forecast Amicus Therapeutics Inc. trends using time seriesJuly 2025 Analyst Calls & Safe Entry Point Alerts - newser.com
Needham Upgrades Amicus Therapeutics(FOLD.US) to Buy Rating, Announces Target Price $14 - 富途牛牛
Technical signs of recovery in Amicus Therapeutics Inc.2025 Investor Takeaways & AI Driven Price Forecasts - newser.com
Using Ichimoku Cloud for Amicus Therapeutics Inc. technicalsWeekly Profit Recap & Reliable Volume Spike Alerts - newser.com
Can Galafold Drive Amicus' Growth Through the Rest of 2025? - sharewise.com
Amicus Therapeutics (NASDAQ:FOLD) Trading Up 6.5%What's Next? - MarketBeat
Amicus Therapeutics Inc Stock (FOLD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Amicus Therapeutics Inc Stock (FOLD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Campbell Bradley L | President and CEO |
Feb 19 '25 |
Sale |
10.00 |
400 |
4,000 |
1,150,657 |
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):